Dr. Chaudhary on Remaining Challenges With CAR T-Cell Therapy

Video

Preet M. Chaudhary, MD, PhD, chief of the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Department of Medicine, professor of Medicine, Ronald H. Bloom Family Chair in Lymphoma Research, and program director of the USC Norris Blood and Marrow Transplant Program, co-Leader of the Molecular Genetics Program, University of Southern California, discusses challenges that oncologists continue to face when treating patients with CAR T-cell therapy.

Preet M. Chaudhary, MD, PhD, chief of the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Department of Medicine, professor of Medicine, Ronald H. Bloom Family Chair in Lymphoma Research, and program director of the USC Norris Blood and Marrow Transplant Program, co-leader of the Molecular Genetics Program, University of Southern California, discusses challenges that oncologists continue to face when treating patients with CAR T-cell therapy.

Chaudhary begins by giving credit to the work of several investigators from multiple major cancer centers across the world, because with their help, this field has been able to overcome logistical issues with the manufacturing and production of CAR T-cell therapy. He hopes that, in the near future, these experts will also be able to overcome regulatory hurdles and achieve FDA approval of these agents.

However, he says, the major challenge that remains in the community is the management of toxicities associated with CAR T-cell therapy. Chaudhary believes that many physicians in this space are simply not equipped to handle patients who may present with, for example, neurological toxicity or cytokine release syndrome. He hopes that these issues will be addressed moving forward.

Most of the success seen thus far with CAR T-cell therapy has been in the treatment of patients with hematologic malignancies, and primarily B-cell malignancies, he explains. Chaudhary is confident that the efficacy of these agents can, and should, be expanded for the treatment of patients with solid tumors and other types of cancer.

Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.